{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:03:08Z","timestamp":1791226988927,"version":"4.1.0"},"reference-count":331,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Copenhagen University Hospital, Hvidovre"},{"DOI":"10.13039\/501100001734","name":"University of Copenhagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Danish Council for Independent"},{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CO-HEP"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.antiviral.2018.07.014","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T02:47:57Z","timestamp":1532659677000},"page":"264-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies"],"prefix":"10.1016","volume":"158","author":[{"given":"Santseharay","family":"Ramirez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.virusres.2006.12.011","article-title":"Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA","volume":"125","author":"Abe","year":"2007","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/hep.510270242","article-title":"Full-length complementary DNA of hepatitis C virus genome from an infectious blood sample","volume":"27","author":"Aizaki","year":"1998","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2013.05.007","article-title":"Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice","volume":"145","author":"Akazawa","year":"2013","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib4","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1128\/JVI.02170-10","article-title":"Identification of new functional regions in hepatitis C virus envelope glycoprotein E2","volume":"85","author":"Albecka","year":"2011","journal-title":"J. Virol."},{"issue":"22","key":"10.1016\/j.antiviral.2018.07.014_bib5","doi-asserted-by":"crossref","first-page":"11523","DOI":"10.1128\/JVI.01185-15","article-title":"Cooperation between the hepatitis C virus p7 and NS5B proteins enhances virion infectivity","volume":"89","author":"Aligeti","year":"2015","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2006.08.018","article-title":"Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes","volume":"46","author":"Aly","year":"2007","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021284","article-title":"Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV)","volume":"6","author":"Aly","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082527","article-title":"Isolation and characterization of highly replicable hepatitis C virus genotype 1a strain HCV-RMT","volume":"8","author":"Arai","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.014_bib9","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1128\/JVI.02200-09","article-title":"Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes","volume":"84","author":"Bankwitz","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(01)00164-4","article-title":"Novel cell culture systems for the hepatitis C virus","volume":"52","author":"Bartenschlager","year":"2001","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.virusres.2007.02.022","article-title":"Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture","volume":"127","author":"Bartenschlager","year":"2007","journal-title":"Virus Res."},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.014_bib12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.014_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","article-title":"Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies","volume":"248","author":"Bartenschlager","year":"2018","journal-title":"Virus Res."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J. Exp. Med."},{"issue":"24","key":"10.1016\/j.antiviral.2018.07.014_bib15","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes","volume":"100","author":"Bartosch","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.antiviral.2018.07.014_bib16","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1128\/JVI.79.13.8217-8229.2005","article-title":"An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies","volume":"79","author":"Bartosch","year":"2005","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/hep.510300137","article-title":"An infectious molecular clone of a Japanese genotype 1b hepatitis C virus","volume":"30","author":"Beard","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib18","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/JVI.72.3.2364-2372.1998","article-title":"Characterization of an autonomous subgenomic pestivirus RNA replicon","volume":"72","author":"Behrens","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.014_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2741\/s449","article-title":"Modeling of HBV and HCV hepatitis with hepatocyte-like cells","volume":"8","author":"Bengrine","year":"2016","journal-title":"Front. Biosci. (Schol Ed)"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib20","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2014.07.019","article-title":"Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication","volume":"147","author":"Berger","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib21","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1128\/JVI.00032-07","article-title":"Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras","volume":"81","author":"Binder","year":"2007","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.antiviral.2011.05.007","article-title":"Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors","volume":"91","author":"Binder","year":"2011","journal-title":"Antivir. Res."},{"issue":"5498","key":"10.1016\/j.antiviral.2018.07.014_bib23","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.antiviral.2018.07.014_bib24","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","article-title":"Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication","volume":"76","author":"Blight","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.014_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India - expanding classification of hepatitis C virus into 8 genotypes","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.014_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002144","article-title":"A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly","volume":"7","author":"Boson","year":"2011","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/j.gastro.2016.11.047","article-title":"Daclatasvir prevents hepatitis C virus infectivity by blocking transfer of the viral genome to assembly sites","volume":"152","author":"Boson","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/135965350701200505","article-title":"Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity","volume":"12","author":"Brochot","year":"2007","journal-title":"Antivir. Ther."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib29","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/hep.20268","article-title":"A critical role for the chimpanzee model in the study of hepatitis C","volume":"39","author":"Bukh","year":"2004","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib30","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1053\/j.gastro.2012.02.016","article-title":"Animal models for the study of hepatitis C virus infection and related liver disease","volume":"142","author":"Bukh","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl. l","key":"10.1016\/j.antiviral.2018.07.014_bib31","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib32","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1073\/pnas.0600551103","article-title":"A milestone for hepatitis C virus research: a virus generated in cell culture is fully viable in vivo","volume":"103","author":"Bukh","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.antiviral.2018.07.014_bib33","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.1073\/pnas.91.17.8239","article-title":"At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide","volume":"91","author":"Bukh","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"17","key":"10.1016\/j.antiviral.2018.07.014_bib34","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.1073\/pnas.91.17.8239","article-title":"Sequence analysis of the core gene of 14 hepatitis C virus genotypes","volume":"91","author":"Bukh","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2007-1007262","article-title":"Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes","volume":"15","author":"Bukh","year":"1995","journal-title":"Semin. Liver Dis."},{"issue":"Suppl. 13","key":"10.1016\/j.antiviral.2018.07.014_bib36","first-page":"3","article-title":"Biology and genetic heterogeneity of hepatitis C virus","volume":"13","author":"Bukh","year":"1995","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1365-2893.2001.00284.x","article-title":"Failure to infect rhesus monkeys with hepatitis C virus strains of genotypes 1a, 2a or 3a","volume":"8","author":"Bukh","year":"2001","journal-title":"J. Viral Hepat."},{"issue":"2\u20133","key":"10.1016\/j.antiviral.2018.07.014_bib38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000050040","article-title":"Studies of hepatitis C virus in chimpanzees and their importance for vaccine development","volume":"44","author":"Bukh","year":"2001","journal-title":"Intervirology"},{"issue":"22","key":"10.1016\/j.antiviral.2018.07.014_bib39","doi-asserted-by":"crossref","first-page":"14416","DOI":"10.1073\/pnas.212532699","article-title":"Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees","volume":"99","author":"Bukh","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.antiviral.2018.07.014_bib40","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1128\/JVI.00142-08","article-title":"Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain","volume":"82","author":"Bukh","year":"2008","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib41","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/651579","article-title":"Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models","volume":"201","author":"Bukh","year":"2010","journal-title":"J. Infect. Dis."},{"issue":"Pt 7","key":"10.1016\/j.antiviral.2018.07.014_bib42","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1099\/vir.0.010983-0","article-title":"Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells","volume":"90","author":"Bungyoku","year":"2009","journal-title":"J. Gen. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065273","article-title":"Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures","volume":"8","author":"Bush","year":"2013","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.antiviral.2018.07.014_bib44","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1128\/JVI.02654-10","article-title":"Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8(+) T cells in early viral evolution","volume":"85","author":"Callendret","year":"2011","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.antiviral.2018.07.014_bib45","doi-asserted-by":"crossref","first-page":"15331","DOI":"10.1128\/JVI.79.24.15331-15341.2005","article-title":"Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry","volume":"79","author":"Callens","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.014_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2017.11.003","article-title":"Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems","volume":"514","author":"Camus","year":"2018","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib47","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/JVI.00684-12","article-title":"Characterization of hepatitis C virus recombinants with chimeric E1\/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry","volume":"87","author":"Carlsen","year":"2013","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib48","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.27298","article-title":"Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a","volume":"60","author":"Carlsen","year":"2014","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.antiviral.2018.07.014_bib49","doi-asserted-by":"crossref","first-page":"8282","DOI":"10.1128\/JVI.01102-13","article-title":"Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission","volume":"87","author":"Catanese","year":"2013","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib50","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2011.10.022","article-title":"An adaptive mutation in NS2 is essential for efficient production of infectious 1b\/2a chimeric hepatitis C virus in cell culture","volume":"422","author":"Chan","year":"2012","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2013.01.005","article-title":"Development of a robust luciferase reporter 1b\/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors","volume":"98","author":"Chan","year":"2013","journal-title":"Antivir. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2018.07.014_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1440-1746.2010.06550.x","article-title":"Hepatitis C virus: how genetic variability affects pathobiology of disease","volume":"26","author":"Chayama","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2174\/1574888X09666140923121234","article-title":"Induced pluripotent stem cells (iPSCs) in the modeling of hepatitis C virus infection","volume":"10","author":"Cheng","year":"2015","journal-title":"Curr. Stem Cell Res. Ther."},{"issue":"4902","key":"10.1016\/j.antiviral.2018.07.014_bib54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib55","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1073\/pnas.88.6.2451","article-title":"Genetic organization and diversity of the hepatitis C virus","volume":"88","author":"Choo","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib56","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jmv.24591","article-title":"Cell culture-adaptive mutations of NS5A affect replication of hepatitis C virus differentially depending on the viral genotypes","volume":"89","author":"Chung","year":"2017","journal-title":"J. Med. Virol."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib57","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1128\/JVI.00538-13","article-title":"Genome-wide analysis of host mRNA translation during hepatitis C virus infection","volume":"87","author":"Colman","year":"2013","journal-title":"J. Virol."},{"issue":"19","key":"10.1016\/j.antiviral.2018.07.014_bib58","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1073\/pnas.0402253101","article-title":"CD81 is an entry coreceptor for hepatitis C virus","volume":"101","author":"Cormier","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.07.014_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.virusres.2017.07.018","article-title":"Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication","volume":"240","author":"Coto-Llerena","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.07.014_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2017.03.017","article-title":"Direct-acting antivirals: the endgame for hepatitis C?","volume":"24","author":"D'Ambrosio","year":"2017","journal-title":"Curr. Opin. Virol."},{"issue":"19","key":"10.1016\/j.antiviral.2018.07.014_bib61","doi-asserted-by":"crossref","first-page":"10805","DOI":"10.1128\/JVI.07235-11","article-title":"Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone","volume":"86","author":"Date","year":"2012","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1348-0421.2012.00437.x","article-title":"Replication and infectivity of a novel genotype 1b hepatitis C virus clone","volume":"56","author":"Date","year":"2012","journal-title":"Microbiol. Immunol."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib63","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1128\/JVI.03174-12","article-title":"Genetic and functional characterization of the N-terminal region of the hepatitis C virus NS2 protein","volume":"87","author":"de la Fuente","year":"2013","journal-title":"J. Virol."},{"issue":"Pt 9","key":"10.1016\/j.antiviral.2018.07.014_bib64","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1099\/vir.0.82872-0","article-title":"Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins","volume":"88","author":"Delgrange","year":"2007","journal-title":"J. Gen. Virol."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006774","article-title":"The amino-terminus of the hepatitis C virus (HCV) p7 viroporin and its cleavage from glycoprotein E2-p7 precursor determine specific infectivity and secretion levels of HCV particle types","volume":"13","author":"Denolly","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.07.014_bib66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2017.10.015","article-title":"A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo","volume":"148","author":"Desombere","year":"2017","journal-title":"Antivir. Res."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib67","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1039\/c3mb70343f","article-title":"Identification and comparative analysis of hepatitis C virus-host cell protein interactions","volume":"9","author":"Dolan","year":"2013","journal-title":"Mol. Biosyst."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000310","article-title":"Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains","volume":"5","author":"Dreux","year":"2009","journal-title":"PLoS Pathog."},{"issue":"2-3","key":"10.1016\/j.antiviral.2018.07.014_bib332","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0014-5793(03)00635-5","volume":"546","author":"Drummer","year":"2003","journal-title":"FEBS Lett."},{"issue":"1 Suppl. l","key":"10.1016\/j.antiviral.2018.07.014_bib69","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jhep.2014.06.031","article-title":"Virology and cell biology of the hepatitis C virus life cycle: an update","volume":"61","author":"Dubuisson","year":"2014","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib70","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4254\/wjh.v7.i6.831","article-title":"Hepatitis C virus genetic variability and evolution","volume":"7","author":"Echeverria","year":"2015","journal-title":"World J. Hepatol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib71","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/JVI.02030-15","article-title":"Pan-genotypic hepatitis C virus inhibition by natural products derived from the wild egyptian artichoke","volume":"90","author":"Elsebai","year":"2015","journal-title":"J. Virol."},{"issue":"7137","key":"10.1016\/j.antiviral.2018.07.014_bib72","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature05654","article-title":"Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry","volume":"446","author":"Evans","year":"2007","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib73","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00945022","article-title":"The quasispecies of hepatitis C virus and the host immune response","volume":"19","author":"Farci","year":"1997","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.antiviral.2018.07.014_bib75","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/1743-422X-8-402","article-title":"Selection of hepatitis C virus resistant to ribavirin","volume":"8","author":"Feigelstock","year":"2011","journal-title":"Virol. J."},{"issue":"18","key":"10.1016\/j.antiviral.2018.07.014_bib76","doi-asserted-by":"crossref","first-page":"9782","DOI":"10.1128\/JVI.78.18.9782-9789.2004","article-title":"Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity","volume":"78","author":"Fernandez","year":"2004","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib77","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/gutjnl-2013-305634","article-title":"Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication","volume":"64","author":"Florimond","year":"2015","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib78","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0966-842X(99)01590-5","article-title":"Quasispecies in viral persistence and pathogenesis of hepatitis C virus","volume":"7","author":"Forns","year":"1999","journal-title":"Trends Microbiol."},{"issue":"24","key":"10.1016\/j.antiviral.2018.07.014_bib79","doi-asserted-by":"crossref","first-page":"13318","DOI":"10.1073\/pnas.230453597","article-title":"Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees","volume":"97","author":"Forns","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib80","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.26685","article-title":"Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release","volume":"59","author":"Foster","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib81","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.26626","article-title":"Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells","volume":"59","author":"Frentzen","year":"2014","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib82","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib83","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/JVI.79.1.380-392.2005","article-title":"Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication","volume":"79","author":"Friebe","year":"2005","journal-title":"J. Virol."},{"issue":"15","key":"10.1016\/j.antiviral.2018.07.014_bib84","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1128\/JVI.00567-12","article-title":"Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus","volume":"86","author":"Fukuhara","year":"2012","journal-title":"J. Virol."},{"issue":"49","key":"10.1016\/j.antiviral.2018.07.014_bib85","doi-asserted-by":"crossref","first-page":"19450","DOI":"10.1073\/pnas.0809879105","article-title":"In vitro selection of a neutralization-resistant hepatitis C virus escape mutant","volume":"105","author":"Gal-Tanamy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Pt 10","key":"10.1016\/j.antiviral.2018.07.014_bib86","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1099\/vir.0.053868-0","article-title":"Analysis of hepatitis C virus core\/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7","volume":"94","author":"Galli","year":"2013","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib87","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1038\/s41598-018-22620-2","article-title":"Antiviral effect of ribavirin against HCV associated with increased frequency of G-to-a and C-to-U transitions in infectious cell culture model","volume":"8","author":"Galli","year":"2018","journal-title":"Sci. Rep."},{"issue":"7294","key":"10.1016\/j.antiviral.2018.07.014_bib88","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.antiviral.2018.07.014_bib89","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.07.014_bib90","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-3527(08)00002-X","article-title":"Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems","volume":"71","author":"Gottwein","year":"2008","journal-title":"Adv. Virus Res."},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib91","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrgastro.2013.136","article-title":"Viral hepatitis: cell-culture-derived HCV-a promising vaccine antigen","volume":"10","author":"Gottwein","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib92","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1053\/j.gastro.2007.08.005","article-title":"Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a\/2a (S52\/JFH1) viruses","volume":"133","author":"Gottwein","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib93","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs","volume":"49","author":"Gottwein","year":"2009","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib94","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies","volume":"84","author":"Gottwein","year":"2010","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.antiviral.2018.07.014_bib95","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1128\/JVI.00049-11","article-title":"Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A","volume":"85","author":"Gottwein","year":"2011","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib96","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","article-title":"Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3\/4A protease recombinant viruses","volume":"141","author":"Gottwein","year":"2011","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib97","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1128\/AAC.01176-13","article-title":"Adapted J6\/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor","volume":"57","author":"Gottwein","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib98","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/AAC.02164-12","article-title":"Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses","volume":"57","author":"Gottwein","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib99","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2005.08.005","article-title":"A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background","volume":"69","author":"Graham","year":"2006","journal-title":"Antivir. Res."},{"issue":"19","key":"10.1016\/j.antiviral.2018.07.014_bib101","doi-asserted-by":"crossref","first-page":"16741","DOI":"10.1074\/jbc.M212602200","article-title":"Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase","volume":"278","author":"Grobler","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib102","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.antiviral.2018.07.014_bib103","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1128\/JVI.75.18.8516-8523.2001","article-title":"Effect of alpha interferon on the hepatitis C virus replicon","volume":"75","author":"Guo","year":"2001","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib104","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hep.29211","article-title":"Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells","volume":"66","author":"Guo","year":"2017","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib105","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00048-17","article-title":"Identification of novel functions for hepatitis C virus envelope glycoprotein E1 in virus entry and assembly","volume":"91","author":"Haddad","year":"2017","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib106","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1073\/pnas.88.5.1711","article-title":"Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end","volume":"88","author":"Han","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.virusres.2009.06.005","article-title":"Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus","volume":"145","author":"Han","year":"2009","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.07.014_bib108","doi-asserted-by":"crossref","first-page":"16247","DOI":"10.1038\/nmicrobiol.2016.247","article-title":"Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture","volume":"2","author":"Harak","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.014_bib109","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-422X-7-36","article-title":"Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway","volume":"7","author":"Hazari","year":"2010","journal-title":"Virol. J."},{"issue":"22","key":"10.1016\/j.antiviral.2018.07.014_bib110","doi-asserted-by":"crossref","first-page":"11905","DOI":"10.1128\/JVI.01548-10","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions","volume":"84","author":"Helle","year":"2010","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070809","article-title":"Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus","volume":"8","author":"Helle","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib112","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1128\/AAC.00533-08","article-title":"Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors","volume":"52","author":"Herlihy","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2018.07.014_bib113","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13638","article-title":"Treatment of hepatitis C: results in real life","volume":"38","author":"Hezode","year":"2018","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib114","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/viro.1999.9603","article-title":"Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees","volume":"256","author":"Hong","year":"1999","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib115","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1073\/pnas.0832180100","article-title":"Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles","volume":"100","author":"Hsu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.07.014_bib116","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2017.10.016","article-title":"Avasimibe: a novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles","volume":"148","author":"Hu","year":"2017","journal-title":"Antivir. Res."},{"issue":"522","key":"10.1016\/j.antiviral.2018.07.014_bib117","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.virol.2018.05.020","article-title":"Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies","volume":"19","author":"Humes","year":"2018","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib118","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1128\/JVI.76.6.2997-3006.2002","article-title":"Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells","volume":"76","author":"Ikeda","year":"2002","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib119","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.bbrc.2005.02.138","article-title":"Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system","volume":"329","author":"Ikeda","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib120","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1128\/JVI.02698-09","article-title":"Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6","volume":"84","author":"Imhof","year":"2010","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib121","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.24172","article-title":"Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)","volume":"53","author":"Imhof","year":"2011","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.antiviral.2018.07.014_bib122","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib123","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1086\/593021","article-title":"Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection","volume":"198","author":"Jensen","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib124","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1128\/AAC.01953-15","article-title":"Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance","volume":"59","author":"Jensen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"17","key":"10.1016\/j.antiviral.2018.07.014_bib125","doi-asserted-by":"crossref","first-page":"8987","DOI":"10.1128\/JVI.00004-12","article-title":"Cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virus","volume":"86","author":"Jiang","year":"2012","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib126","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11908-017-0578-5","article-title":"Hepatitis C virus-genotype 3: update on current and emergent therapeutic interventions","volume":"19","author":"Johnson","year":"2017","journal-title":"Curr. Infect. Dis. Rep."},{"issue":"16","key":"10.1016\/j.antiviral.2018.07.014_bib127","doi-asserted-by":"crossref","first-page":"8374","DOI":"10.1128\/JVI.00690-07","article-title":"Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus","volume":"81","author":"Jones","year":"2007","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nbt.1604","article-title":"Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system","volume":"28","author":"Jones","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"5740","key":"10.1016\/j.antiviral.2018.07.014_bib129","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib130","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/JVI.06242-11","article-title":"Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122","volume":"86","author":"Kambara","year":"2012","journal-title":"J. Virol."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2018.07.014_bib131","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.virusres.2009.04.002","article-title":"Cell culture-adaptive mutations in the NS5B gene of hepatitis C virus with delayed replication and reduced cytotoxicity","volume":"144","author":"Kang","year":"2009","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib133","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/jmv.1055","article-title":"Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient","volume":"64","author":"Kato","year":"2001","journal-title":"J. Med. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib134","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/j.gastro.2003.09.023","article-title":"Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon","volume":"125","author":"Kato","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib135","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/hep.22422","article-title":"Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation","volume":"48","author":"Kato","year":"2008","journal-title":"Hepatology"},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2018.07.014_bib136","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.virusres.2009.08.006","article-title":"Efficient replication systems for hepatitis C virus using a new human hepatoma cell line","volume":"146","author":"Kato","year":"2009","journal-title":"Virus Res."},{"issue":"23","key":"10.1016\/j.antiviral.2018.07.014_bib137","doi-asserted-by":"crossref","first-page":"13168","DOI":"10.1128\/JVI.01362-07","article-title":"Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant","volume":"81","author":"Kaul","year":"2007","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.antiviral.2018.07.014_bib138","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib139","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1128\/JVI.01710-06","article-title":"Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions","volume":"81","author":"Keck","year":"2007","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.antiviral.2018.07.014_bib140","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations","volume":"85","author":"Keck","year":"2011","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"Keck","year":"2012","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib142","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/JVI.01941-12","article-title":"Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein","volume":"87","author":"Keck","year":"2013","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004297","article-title":"Gatherer D, Patel AH, Foung SK. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423","volume":"10","author":"Keck","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.07.014_bib144","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1099\/jgv.0.000932","article-title":"Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon","volume":"98","author":"Kelly","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"16","key":"10.1016\/j.antiviral.2018.07.014_bib145","doi-asserted-by":"crossref","first-page":"8814","DOI":"10.1128\/JVI.02824-06","article-title":"Monitoring the antiviral effect of alpha interferon on individual cells","volume":"81","author":"Kim","year":"2007","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib146","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/hep.27197","article-title":"Development of hepatitis C virus genotype 3a cell culture system","volume":"60","author":"Kim","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib147","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1128\/JVI.02052-13","article-title":"Hepatitis C virus RNA replication and virus particle assembly require specific dimerization of the NS4A protein transmembrane domain","volume":"88","author":"Kohlway","year":"2014","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib148","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1128\/jvi.70.6.3363-3371.1996","article-title":"Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA","volume":"70","author":"Kolykhalov","year":"1996","journal-title":"J. Virol."},{"issue":"5325","key":"10.1016\/j.antiviral.2018.07.014_bib149","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.277.5325.570","article-title":"Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA","volume":"277","author":"Kolykhalov","year":"1997","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib150","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/JVI.74.4.2046-2051.2000","article-title":"Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo","volume":"74","author":"Kolykhalov","year":"2000","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.014_bib151","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1128\/JVI.02460-05","article-title":"Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses","volume":"80","author":"Koutsoudakis","year":"2006","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023587","article-title":"Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantation","volume":"6","author":"Koutsoudakis","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053254","article-title":"A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus","volume":"7","author":"Koutsoudakis","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib154","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02354-16","article-title":"Oligonucleotide-lipid conjugates forming G-quadruplex structures are potent and pangenotypic hepatitis C virus entry inhibitors in vitro and ex vivo","volume":"61","author":"Koutsoudakis","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib155","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1128\/JVI.75.10.4614-4624.2001","article-title":"Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations","volume":"75","author":"Krieger","year":"2001","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib156","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/hep.21377","article-title":"A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes","volume":"44","author":"Kuiken","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib157","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.25738","article-title":"Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: a relevant ex vivo model of liver infection","volume":"56","author":"Lagaye","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib158","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Pt 6","key":"10.1016\/j.antiviral.2018.07.014_bib159","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1099\/0022-1317-82-6-1291","article-title":"Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence","volume":"82","author":"Lanford","year":"2001","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.virol.2006.07.019","article-title":"Hepatitis C virus genotype 1b chimeric replicon containing genotype 3 NS5A domain","volume":"355","author":"Lanford","year":"2006","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib161","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/ilar\/ilx028","article-title":"The chimpanzee model of viral hepatitis: advances in understanding the immune response and treatment of viral hepatitis","volume":"58","author":"Lanford","year":"2017","journal-title":"ILAR J."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib162","doi-asserted-by":"crossref","DOI":"10.1002\/hep.20542","article-title":"Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus","volume":"41","author":"Lavillette","year":"2005","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib163","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059776","article-title":"A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans","volume":"8","author":"Law","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.014_bib165","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02141-17","article-title":"Role of the E2 hypervariable region (HVR1) in the immunogenicity of a recombinant HCV vaccine","volume":"92","author":"Law","year":"2018","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib166","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2353\/ajpath.2007.060789","article-title":"Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes","volume":"170","author":"Lazaro","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.antiviral.2018.07.014_bib167","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antivir. Res."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib168","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1073\/pnas.1016606108","article-title":"MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR","volume":"108","author":"Li","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib169","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.virol.2011.10.002","article-title":"Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon","volume":"421","author":"Li","year":"2011","journal-title":"Virology"},{"issue":"18","key":"10.1016\/j.antiviral.2018.07.014_bib170","doi-asserted-by":"crossref","first-page":"E1101","DOI":"10.1073\/pnas.1203829109","article-title":"Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"48","key":"10.1016\/j.antiviral.2018.07.014_bib171","doi-asserted-by":"crossref","first-page":"19757","DOI":"10.1073\/pnas.1218260109","article-title":"Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib172","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2013.11.009","article-title":"Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004163","article-title":"Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle","volume":"10","author":"Li","year":"2014","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib174","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/JVI.02877-14","article-title":"Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77","volume":"89","author":"Li","year":"2015","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.antiviral.2018.07.014_bib175","doi-asserted-by":"crossref","first-page":"10486","DOI":"10.1128\/JVI.01462-16","article-title":"Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice","volume":"90","author":"Li","year":"2016","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib176","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1099\/jgv.0.000445","article-title":"Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir","volume":"97","author":"Li","year":"2016","journal-title":"J. Gen. Virol."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib177","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/infdis\/jix180","article-title":"Immunization with a subunit hepatitis C virus vaccine elicits Pan-Genotypic neutralizing antibodies and intrahepatic t-cell responses in nonhuman primates","volume":"215","author":"Li","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.014_bib178","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.virol.2018.03.001","article-title":"Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1)","volume":"518","author":"Li","year":"2018","journal-title":"Virology"},{"issue":"5734","key":"10.1016\/j.antiviral.2018.07.014_bib179","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib180","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.0511218103","article-title":"Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro","volume":"103","author":"Lindenbach","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib181","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.antiviral.2010.11.004","article-title":"Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase","volume":"89","author":"Liu","year":"2011","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib182","article-title":"A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.07.014_bib183","doi-asserted-by":"crossref","first-page":"30939","DOI":"10.1038\/srep30939","article-title":"Efficient suppression of hepatitis C virus replication by combination treatment with miR-122 antagonism and direct-acting antivirals in cell culture systems","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"issue":"27","key":"10.1016\/j.antiviral.2018.07.014_bib184","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib185","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/jm401401n","article-title":"On the history of hepatitis C virus cell culture systems","volume":"57","author":"Lohmann","year":"2014","journal-title":"J. Med. Chem."},{"issue":"5424","key":"10.1016\/j.antiviral.2018.07.014_bib186","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib187","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1053\/j.gastro.2011.06.010","article-title":"Mouse hepatic cells support assembly of infectious hepatitis C virus particles","volume":"141","author":"Long","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib188","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.virol.2003.08.038","article-title":"Analysis of mutant NS5B proteins encoded by isolates from chimpanzees chronically infected following clonal HCV RNA inoculation","volume":"317","author":"Lou","year":"2003","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib189","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2013.04.030","article-title":"Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates","volume":"443","author":"Lu","year":"2013","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib190","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/JVI.02929-13","article-title":"A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate","volume":"88","author":"Lu","year":"2014","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib191","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2893.2004.00525.x","article-title":"Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells","volume":"11","author":"Maekawa","year":"2004","journal-title":"J. Viral Hepat."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib192","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/JVI.73.4.3317-3325.1999","article-title":"Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus","volume":"73","author":"Major","year":"1999","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib193","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.20239","article-title":"Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees","volume":"39","author":"Major","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib194","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/jvi.66.5.3225-3229.1992","article-title":"Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution","volume":"66","author":"Martell","year":"1992","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.antiviral.2018.07.014_bib195","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1128\/JVI.00826-08","article-title":"Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles","volume":"82","author":"Masaki","year":"2008","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib196","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.virol.2008.03.027","article-title":"Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death","volume":"376","author":"Mateu","year":"2008","journal-title":"Virology"},{"issue":"15","key":"10.1016\/j.antiviral.2018.07.014_bib197","doi-asserted-by":"crossref","first-page":"7758","DOI":"10.1128\/JVI.00039-15","article-title":"Adaptive mutations enhance assembly and cell-to-cell transmission of a high-titer hepatitis C virus genotype 5a core-NS2 JFH1-based recombinant","volume":"89","author":"Mathiesen","year":"2015","journal-title":"J. Virol."},{"issue":"Pt 1","key":"10.1016\/j.antiviral.2018.07.014_bib198","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1099\/vir.0.026385-0","article-title":"The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity","volume":"92","author":"McCaffrey","year":"2011","journal-title":"J. Gen. Virol."},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib199","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1099\/jgv.0.000530","article-title":"Flexible and rapid construction of viral chimeras applied to hepatitis C virus","volume":"97","author":"McClure","year":"2016","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib200","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","author":"McGivern","year":"2014","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib201","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1073\/pnas.0611267104","article-title":"Evidence for a functional RNA element in the hepatitis C virus core gene","volume":"104","author":"McMullan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.07.014_bib202","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001095","article-title":"Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a","author":"Mejer","year":"2018","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib203","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1074\/jbc.M110.175018","article-title":"Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome","volume":"286","author":"Merz","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib204","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/v8060176","article-title":"Mouse systems to model hepatitis C virus treatment and associated resistance","volume":"8","author":"Mesalam","year":"2016","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib205","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1073\/pnas.0501275102","article-title":"Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1","volume":"102","author":"Meunier","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib206","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/infdis\/jir511","article-title":"Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus","volume":"204","author":"Meunier","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib207","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/JVI.01443-07","article-title":"Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent","volume":"82","author":"Molina","year":"2008","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib208","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbrc.2008.04.005","article-title":"New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C","volume":"371","author":"Mori","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib209","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12866-016-0846-9","article-title":"Production of infectious HCV genotype 1b virus in cell culture using a novel Set of adaptive mutations","volume":"16","author":"Mori","year":"2016","journal-title":"BMC Microbiol."},{"issue":"15","key":"10.1016\/j.antiviral.2018.07.014_bib210","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1128\/JVI.02088-06","article-title":"The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells","volume":"81","author":"Murayama","year":"2007","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib211","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000885","article-title":"RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells","volume":"6","author":"Murayama","year":"2010","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib212","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1128\/JVI.05386-11","article-title":"Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1","volume":"86","author":"Murayama","year":"2012","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib213","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00273-16","article-title":"Completion of the entire hepatitis C virus life cycle in Vero cells derived from monkey kidney","volume":"7","author":"Murayama","year":"2016","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib214","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02124-16","article-title":"Amino acid mutations in the NS4A region of hepatitis C virus contribute to viral replication and infectious virus production","volume":"91","author":"Murayama","year":"2017","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib215","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/JCM.02831-14","article-title":"Hepatitis C virus genotype 7, a new genotype originating from central Africa","volume":"53","author":"Murphy","year":"2015","journal-title":"J. Clin. Microbiol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib216","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1053\/j.gastro.2005.12.030","article-title":"The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity","volume":"130","author":"Nanda","year":"2006","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib217","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.014_bib218","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fmicb.2018.00395","article-title":"Signals involved in regulation of hepatitis C virus RNA genome translation and replication","volume":"9","author":"Niepmann","year":"2018","journal-title":"Front. Microbiol."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib219","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.29096","article-title":"Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles","volume":"65","author":"Oliveira","year":"2017","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071039","article-title":"Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis","volume":"8","author":"Ortega-Prieto","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib221","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.antiviral.2018.07.014_bib222","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.antiviral.2018.07.014_bib223","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding","volume":"80","author":"Owsianka","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.014_bib224","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nmicrobiol.2015.18","article-title":"Hepatitis C virus's next top models?","volume":"1","author":"Paul","year":"2016","journal-title":"Nat. Microbiol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1089-3261(02)00065-X","article-title":"Hepatitis C virus genetic variability: pathogenic and clinical implications","volume":"7","author":"Pawlotsky","year":"2003","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2018.07.014_bib226","first-page":"261","article-title":"Hepatitis C virus population dynamics during infection","volume":"299","author":"Pawlotsky","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib227","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.gastro.2015.01.002","article-title":"Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014","volume":"148","author":"Pawlotsky","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib228","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib229","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/hep.26524","article-title":"Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies","volume":"58","author":"Pedersen","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062674","article-title":"Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome","volume":"8","author":"Pedersen","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib231","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2012.09.033","article-title":"Development of robust hepatitis C virus genotype 4 subgenomic replicons","volume":"144","author":"Peng","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib232","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00037-17","article-title":"Efficient hepatitis C virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors","volume":"61","author":"Pham","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib233","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1053\/j.gastro.2018.02.017","article-title":"HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models","volume":"154","author":"Pham","year":"2018","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.antiviral.2018.07.014_bib234","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1073\/pnas.0504877103","article-title":"Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras","volume":"103","author":"Pietschmann","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000475","article-title":"Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations","volume":"5","author":"Pietschmann","year":"2009","journal-title":"PLoS Pathog."},{"issue":"7231","key":"10.1016\/j.antiviral.2018.07.014_bib236","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nature07684","article-title":"Human occludin is a hepatitis C virus entry factor required for infection of mouse cells","volume":"457","author":"Ploss","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib237","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1053\/j.gastro.2010.06.058","article-title":"Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes","volume":"139","author":"Podevin","year":"2010","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib238","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1128\/JVI.01760-10","article-title":"Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics","volume":"85","author":"Pokrovskii","year":"2011","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib239","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib240","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/BC20090125","article-title":"Role of lipid metabolism in hepatitis C virus assembly and entry","volume":"102","author":"Popescu","year":"2010","journal-title":"Biol. Cell."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib241","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.virol.2010.10.034","article-title":"Hepatitis C virus expressing flag-tagged envelope protein 2 has unaltered infectivity and density, is specifically neutralized by flag antibodies and can be purified by affinity chromatography","volume":"409","author":"Prentoe","year":"2011","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib242","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.01594-10","article-title":"Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization","volume":"85","author":"Prentoe","year":"2011","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib243","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/JVI.02017-13","article-title":"Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus","volume":"88","author":"Prentoe","year":"2014","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib244","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1136\/gutjnl-2015-310300","article-title":"HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice","volume":"65","author":"Prentoe","year":"2016","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib245","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/hep.28705","article-title":"Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity","volume":"64","author":"Prentoe","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.07.014_bib246","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2016.3","article-title":"Entry inhibitors: new advances in HCV treatment","volume":"5","author":"Qian","year":"2016","journal-title":"Emerg. Microb. Infect."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2018.07.014_bib247","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2012.11.010","article-title":"The Arg719 residue at the C-terminal end of the stem region in hepatitis C virus JFH-1 E2 glycoprotein promotes viral infection","volume":"172","author":"Qin","year":"2013","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib248","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.26660","article-title":"Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors","volume":"59","author":"Ramirez","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib249","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib250","first-page":"117","article-title":"New insights into HCV replication: potential antiviral targets","volume":"19","author":"Rice","year":"2011","journal-title":"Top Antivir. Med."},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib251","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01982-17","article-title":"Identification of piperazinylbenzenesulfonamides as new inhibitors of Claudin-1 trafficking and hepatitis C virus entry","volume":"92","author":"Riva","year":"2018","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib252","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s007050050479","article-title":"Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy","volume":"143","author":"Robertson","year":"1998","journal-title":"Arch. Virol."},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.014_bib253","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1073\/pnas.0800422105","article-title":"Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus","volume":"105","author":"Russell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib254","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2893.2009.01111.x","article-title":"Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77\/JFH1 chimeric infectious virus particles","volume":"16","author":"Russell","year":"2009","journal-title":"J. Viral Hepat."},{"issue":"4A","key":"10.1016\/j.antiviral.2018.07.014_bib255","first-page":"13.1","article-title":"Development of hepatocyte-like cell derived from human induced pluripotent stem cell as a host for clinically isolated hepatitis C virus","volume":"42","author":"Sa-Ngiamsuntorn","year":"2017","journal-title":"Curr. Protoc. Stem Cell Biol."},{"issue":"14","key":"10.1016\/j.antiviral.2018.07.014_bib256","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.00586-11","article-title":"Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step","volume":"85","author":"Sabo","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib257","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.24399","article-title":"In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis","volume":"54","author":"Saeed","year":"2011","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib258","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1128\/AAC.01256-12","article-title":"Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells","volume":"56","author":"Saeed","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib259","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.gastro.2012.09.017","article-title":"Replication of hepatitis C virus genotype 3a in cultured cells","volume":"144","author":"Saeed","year":"2013","journal-title":"Gastroenterology"},{"issue":"7566","key":"10.1016\/j.antiviral.2018.07.014_bib260","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature14899","article-title":"SEC14L2 enables pan-genotype HCV replication in cell culture","volume":"524","author":"Saeed","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib261","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.antiviral.2018.07.014_bib262","doi-asserted-by":"crossref","first-page":"11646","DOI":"10.1073\/pnas.1834545100","article-title":"The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences","volume":"100","author":"Sakai","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.antiviral.2018.07.014_bib263","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1128\/JVI.01774-06","article-title":"In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells","volume":"81","author":"Sakai","year":"2007","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib264","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib265","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/JVI.02144-06","article-title":"Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes","volume":"81","author":"Schaller","year":"2007","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.014_bib266","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib267","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.0711044105","article-title":"Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization","volume":"105","author":"Scheel","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib268","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1128\/JVI.01605-10","article-title":"Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations","volume":"85","author":"Scheel","year":"2011","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib269","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1053\/j.gastro.2010.11.036","article-title":"Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha","volume":"140","author":"Scheel","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib270","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1128\/JVI.02177-10","article-title":"A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes","volume":"85","author":"Schmitt","year":"2011","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.014_bib271","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1073\/pnas.1121400109","article-title":"Modeling hepatitis C virus infection using human induced pluripotent stem cells","volume":"109","author":"Schwartz","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib272","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006916","article-title":"Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma","volume":"14","author":"Sekhar","year":"2018","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib273","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nano.2016.08.018","article-title":"Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture","volume":"13","author":"Sepulveda-Crespo","year":"2017","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.014_bib274","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.02929-15","article-title":"Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants: in vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle","volume":"60","author":"Serre","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib275","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.014_bib276","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1128\/JVI.03839-13","article-title":"Novel permissive cell lines for complete propagation of hepatitis C virus","volume":"88","author":"Shiokawa","year":"2014","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib277","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jhep.2012.04.012","article-title":"Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study gets personal","volume":"57","author":"Si-Tayeb","year":"2012","journal-title":"J. Hepatol."},{"issue":"22","key":"10.1016\/j.antiviral.2018.07.014_bib278","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1128\/JVI.01008-09","article-title":"Structural and functional analysis of hepatitis C virus strain JFH1 polymerase","volume":"83","author":"Simister","year":"2009","journal-title":"J. Virol."},{"issue":"Pt 11","key":"10.1016\/j.antiviral.2018.07.014_bib279","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1099\/0022-1317-74-11-2391","article-title":"Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region","volume":"74","author":"Simmonds","year":"1993","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib280","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib281","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1099\/jgv.0.000672","article-title":"Ictv Report consortium. ICTV virus taxonomy profile: Flaviviridae","volume":"98","author":"Simmonds","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib282","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.014_bib283","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1099\/jgv.0.000612","article-title":"Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family","volume":"97","author":"Smith","year":"2016","journal-title":"J. Gen. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib284","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2013.07.026","article-title":"Hepatic cells derived from induced pluripotent stem cells of pigtail macaques support hepatitis C virus infection","volume":"145","author":"Sourisseau","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.07.014_bib285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs) - a new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib286","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/infdis\/jit503","article-title":"Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study","volume":"209","author":"Sulkowski","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib287","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib288","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","article-title":"Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors","volume":"54","author":"Syder","year":"2011","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib289","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbrc.2010.04.081","article-title":"Biological properties of purified recombinant HCV particles with an epitope-tagged envelope","volume":"395","author":"Takahashi","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib290","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1006\/bbrc.1995.2526","article-title":"A novel sequence found at the 3' terminus of hepatitis C virus genome","volume":"215","author":"Tanaka","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2018.07.014_bib291","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.antiviral.2016.12.009","article-title":"A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals","volume":"139","author":"Tao","year":"2017","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib292","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/JVI.06492-11","article-title":"Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization","volume":"86","author":"Tarr","year":"2012","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib293","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/gast.2001.28669","article-title":"Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus","volume":"121","author":"Thomson","year":"2001","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib294","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1128\/JVI.01748-06","article-title":"Superinfection exclusion in cells infected with hepatitis C virus","volume":"81","author":"Tscherne","year":"2007","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib295","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1099\/jgv.0.000537","article-title":"Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay","volume":"97","author":"Urbanowicz","year":"2016","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib296","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006214","article-title":"Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A","volume":"13","author":"Velazquez-Moctezuma","year":"2017","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.014_bib297","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.28989","article-title":"The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in Guinea pigs","volume":"65","author":"Vietheer","year":"2017","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.014_bib298","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib299","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.01874-12","article-title":"In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.014_bib300","article-title":"A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey","author":"Wang","year":"2017","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.014_bib301","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3748\/wjg.v24.i12.1299","article-title":"Cell culture-adaptive mutations in hepatitis C virus promote viral production by enhancing viral replication and release","volume":"24","author":"Wang","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.014_bib302","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1099\/jgv.0.000608","article-title":"Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles","volume":"97","author":"Wasilewski","year":"2016","journal-title":"J. Gen. Virol."},{"issue":"13","key":"10.1016\/j.antiviral.2018.07.014_bib303","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/1873-3468.12157","article-title":"In vivo models of hepatitis B and C virus infection","volume":"590","author":"Winer","year":"2016","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib304","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/AAC.02932-15","article-title":"Enhancement of the replication of hepatitis C virus replicons of genotypes 1 to 4 by manipulation of CpG and UpA dinucleotide frequencies and use of cell lines expressing SECL14L2 for antiviral resistance testing","volume":"60","author":"Witteveldt","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2008.01066.x","article-title":"Hepatitis C virus replicons: dinosaurs still in business?","volume":"16","author":"Woerz","year":"2009","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib306","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.virol.2012.03.025","article-title":"Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a","volume":"429","author":"Wong","year":"2012","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib307","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3390\/v2081718","article-title":"Targeting HCV entry for development of therapeutics","volume":"2","author":"Wong-Staal","year":"2010","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.antiviral.2018.07.014_bib308","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1128\/AAC.03534-14","article-title":"Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents","volume":"58","author":"Wose Kinge","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib309","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.virusres.2010.11.009","article-title":"A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication","volume":"155","author":"Wu","year":"2011","journal-title":"Virus Res."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004128","article-title":"Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents","volume":"10","author":"Xiao","year":"2014","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib311","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/gutjnl-2013-306155","article-title":"Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C","volume":"64","author":"Xiao","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib312","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1872-034X.2010.00771.x","article-title":"Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture","volume":"41","author":"Yamamoto","year":"2011","journal-title":"Hepatol. Res."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.014_bib313","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nm.3610","article-title":"Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation","volume":"20","author":"Yamane","year":"2014","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.antiviral.2018.07.014_bib314","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.94.16.8738","article-title":"Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee","volume":"94","author":"Yanagi","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/viro.1998.9092","article-title":"Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo","volume":"244","author":"Yanagi","year":"1998","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib316","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1073\/pnas.96.5.2291","article-title":"In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone","volume":"96","author":"Yanagi","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib317","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1006\/viro.1999.9889","article-title":"Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras","volume":"262","author":"Yanagi","year":"1999","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.014_bib318","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1073\/pnas.0510727103","article-title":"Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells","volume":"103","author":"Yi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib319","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1128\/JVI.01890-06","article-title":"Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus","volume":"81","author":"Yi","year":"2007","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000403","article-title":"Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation","volume":"5","author":"Yi","year":"2009","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.014_bib321","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.03540-13","article-title":"Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee","volume":"88","author":"Yi","year":"2014","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.014_bib322","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2016-312208","article-title":"Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model","volume":"67","author":"Yokokawa","year":"2018","journal-title":"Gut"},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2018.07.014_bib323","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbrc.2011.11.007","article-title":"Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection","volume":"416","author":"Yoshida","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib324","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/JVI.01796-07","article-title":"3' RNA elements in hepatitis C virus replication: kissing partners and long poly(U)","volume":"82","author":"You","year":"2008","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.antiviral.2018.07.014_bib325","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma","volume":"101","author":"Yu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.014_bib326","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1128\/AAC.01780-13","article-title":"Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture","volume":"58","author":"Yu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.014_bib327","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.78.3.1448-1455.2004","article-title":"CD81 is required for hepatitis C virus glycoprotein-mediated viral infection","volume":"78","author":"Zhang","year":"2004","journal-title":"J. Virol."},{"issue":"26","key":"10.1016\/j.antiviral.2018.07.014_bib328","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"22","key":"10.1016\/j.antiviral.2018.07.014_bib329","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1128\/JVI.01307-06","article-title":"Persistent hepatitis C virus infection in vitro: coevolution of virus and host","volume":"80","author":"Zhong","year":"2006","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.014_bib330","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01253-17","article-title":"NS3 from hepatitis C virus strain JFH-1 is an unusually robust helicase that is primed to bind and unwind viral RNA","volume":"92","author":"Zhou","year":"2018","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.antiviral.2018.07.014_bib331","doi-asserted-by":"crossref","first-page":"10499","DOI":"10.1128\/JVI.01011-16","article-title":"A library of infectious hepatitis C viruses with engineered mutations in the E2 gene reveals growth-adaptive mutations that modulate interactions with scavenger receptor class B type I","volume":"90","author":"Zuiani","year":"2016","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:30:55Z","timestamp":1759062655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218303279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":331,"alternative-id":["S0166354218303279"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.014","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}